1. Home
  2. GROW vs XLO Comparison

GROW vs XLO Comparison

Compare GROW & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo U.S. Global Investors Inc.

GROW

U.S. Global Investors Inc.

HOLD

Current Price

$2.69

Market Cap

32.7M

Sector

Finance

ML Signal

HOLD

XLO

Xilio Therapeutics Inc.

HOLD

Current Price

$8.37

Market Cap

49.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GROW
XLO
Founded
1968
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
32.7M
49.8M
IPO Year
1995
2021

Fundamental Metrics

Financial Performance
Metric
GROW
XLO
Price
$2.69
$8.37
Analyst Decision
Buy
Analyst Count
0
1
Target Price
N/A
$28.00
AVG Volume (30 Days)
15.3K
33.5K
Earning Date
05-11-2026
05-14-2026
Dividend Yield
3.53%
N/A
EPS Growth
N/A
N/A
EPS
0.27
N/A
Revenue
$23,850,609.00
$43,766,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$168.77
P/E Ratio
$9.85
N/A
Revenue Growth
N/A
589.88
52 Week Low
$2.20
$0.46
52 Week High
$3.65
$9.25

Technical Indicators

Market Signals
Indicator
GROW
XLO
Relative Strength Index (RSI) 50.65 53.90
Support Level $2.35 $0.62
Resistance Level $2.73 $9.03
Average True Range (ATR) 0.10 0.49
MACD 0.01 -0.02
Stochastic Oscillator 56.03 51.88

Price Performance

Historical Comparison
GROW
XLO

About GROW U.S. Global Investors Inc.

US Global Investors Inc is a registered investment advisory firm. The company manages the following business segments: Investment management services; through which the company offers, to U.S. Global Investors Funds (USGIF or the Funds) and exchange-traded fund (ETF) clients, a range of investment management products and services to meet the needs of individual and institutional investors; and Corporate Investments, through which the company invests for its own account in an effort to add growth and value to its cash position. It derives all its revenue from Investment management services.

About XLO Xilio Therapeutics Inc.

Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.

Share on Social Networks: